Stability Indicating RP-HPLC Method Development for the Estimation of Molnupiravir in Capsule Dosage Form
Abstract
In recent years much more attention has gained by antiviral drugs because of severe acute respiratory syndrome coronavirus-2 (SARS-CoV) infection. Molnupiravir is one of the favorable drugs for SARS-CoV-2 treatment. The present study aimed to develop and validate a simple, rapid, stable, selective, sensitive, accurate, robust, and economical RP-HPLC method for determining molnupiravir in its capsule dosage form. The chromatographic separation was achieved on inert sustain C18 column (250 mm x 4.6 mm x 5 μ) at 40°. Isocratic elution was performed with 25 mM KH2PO4 buffer (pH 3.0) and methanol (60:40 v/v) as mobile phase at flow rate of 1.0 mL/min with 50 μL injection volume. The detection was conceded out at 242 nm. The developed RP-HPLC method yielded a suitable retention time of 4.2 minutes for molnupiravir. The developed method was validated according to the International Council on Harmonization (ICH) guidelines and established to be linear in the range of 10 to 70 μg/mL with a linear regression coefficient of 0.9993. The %RSD for the method precision and system precision was found to be less than 2.0%. The %assay of the formulation is 101.52%. The LoD and LoQ were found to be 0.25 and 0.75 μg/mL, respectively. The specificity of the method established using forced degradation studies in which the drug is subjected to the stressed conditions such as thermal, acidic, basic oxidative and photolytic degradation. The developed and validated RP-HPLC method for molnupiravir takes short time and can be used for routine quality analysis of marketed Molnupiravir in capsule dosage form.
Keywords:
Molnupiravir, RP-HPLC, Validation, Optimization, COVID19.DOI
https://doi.org/10.25004/IJPSDR.2023.150301References
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar 12;579(7798):265–9.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb 15;395(10223):497–506.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar 28;395(10229):1054–62.
Painter GR, Natchus MG, Cohen O, Holman W, Painter WP. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Vol. 50, Current Opinion in Virology. Elsevier B.V.; 2021. p. 17–22.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine. 2020 Nov 5;383(19):1813–26.
Teoh SL, Lim YH, Lai NM, Lee SWH. Directly Acting Antivirals for COVID-19: Where Do We Stand? Front Microbiol. 2020 Aug 5;11.
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. New England Journal of Medicine[Internet]. 2021Feb 11;384(6):497–511. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2023184
Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Research. 2020 Apr 1;218:16–28.
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021 Jan 1;6(1):11–8.
Robson F, Khan KS, Le TK, Paris C, Demirbag S, Barfuss P, et al. Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting. Vol. 79, Molecular Cell. Cell Press; 2020. p. 710–27.
Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. RNA 3′-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9372–7.
Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021 May 1;65(5).
Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. Vol. 297, Journal of Biological Chemistry. American Society for Biochemistry and Molecular Biology Inc.; 2021.
Gupta V, Jain ADKJ, N.S G, Guptan K. Development and validation of HPLC method - a review. International Research Journal of Pharmaceutical and Applied Sciences[Internet]. 2012 Aug 31;2(4):17–25. Available from: https://scienztech.org/index.php/irjpas/article/view/307
Amara A, Penchala SD, Else L, Hale C, FitzGerald R, Walker L, et al. The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva. J Pharm Biomed Anal. 2021 Nov 30;206:114356.
Reçber T, Timur SS, Erdoğan Kablan S, Yalçın F, Karabulut TC, Neslihan Gürsoy R, et al. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. J Pharm Biomed Anal. 2022 May 30;214.
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised tripartite guideline validation of analytical procedures: text and methodology Q2(R1).
Singh R. Current trends in forced degradation study for pharmaceutical product development Synthesis and Pharmacological Evaluation of Neuroprotective Heterosteroids View project[Internet]. Vol. 3, J Pharm Educ Res. 2012. Available from: https://www.researchgate.net/publication/263919674
Kshirsagar MB, Mahajan MP, Sawant SD. Method Development and Validation by RP-HPLC for Estimation of Topiramate in Bulk and Pharmaceutical Dosage form. International Journal of ChemTech Research 2017;10(7): 843-849.
Published
Abstract Display: 920 
PDF Downloads: 1106 
